Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience

被引：0
|
作者：
Grilo, I. T. [1 ]
Couto, M. E. [2 ]
Freitas, J. F. [3 ]
Pereira, D. P. [2 ]
Moreira, C. [2 ]
Chacim, S. [2 ]
Domingues, N. [2 ]
Santo, A. E. [2 ]
Martins, A. [2 ]
Viterbo, L. [2 ]
Oliveira, I. [2 ]
Moreira, I. [2 ]
Mariz, J. M. [2 ]
机构：
[1] Ctr Hosp Tras Os Montes & Alto Douro, Oncohematol Dept, EPE, Chaves, Portugal
[2] IPO Porto, Porto, Portugal
[3] IPO Porto, Hematooncol Dept, Porto, Portugal
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz413.060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Hideki Goto
    Satoshi Ito
    Masahiro Kizaki
    Masaki Yamaguchi
    Noriko Fukuhara
    Koji Kato
    Toko Saito
    Yasuhito Terui
    Sumiko Okubo
    Tomomi Soshin
    Jiewei Zeng
    Hideyuki Honda
    Mohamed Badawi
    Jeremy A. Ross
    Koji Izutsu
    [J]. International Journal of Clinical Oncology, 2024, 29 : 232 - 240
  • [32] Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Nishikawa, Tomoaki
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (02) : 98 - 100
  • [33] Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis
    Rule, Simon
    Dreyling, Martin
    Goy, Andre
    Hess, Georg
    Auer, Rebecca
    Kahl, Brad S.
    Hernandez-Rivas, Jose Angel
    Londhe, Anil
    Clow, Fong
    Deshpande, Sanjay
    Parisi, Lori
    Wang, Michael
    [J]. BLOOD, 2017, 130
  • [34] Ibrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Retrospective Single Center Experience from India
    Ahmed, Rayaz
    Bhurani, Dinesh
    Agarwal, Narendra
    Kapoor, Jyotsna
    Gurha, Neha
    Shah, Manan
    Narang, Prashant
    [J]. BLOOD, 2018, 132
  • [35] Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
    Tam, Constantine S.
    Opat, Stephen
    Simpson, David
    Cull, Gavin
    Munoz, Javier
    Phillips, Tycel J.
    Kim, Won Seog
    Rule, Simon
    Atwal, Siminder Kaur
    Wei, Rachel
    Novotny, William
    Huang, Jane
    Wang, Michael
    Trotman, Judith
    [J]. BLOOD ADVANCES, 2021, 5 (12) : 2577 - 2585
  • [36] Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
    Samad, Nousheen
    Younes, Anas
    [J]. ONCOTARGETS AND THERAPY, 2010, 3 : 167 - 178
  • [37] Autologous Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
    Shah, Bijal D.
    Little, Bryan J.
    Cultrera, Jennifer
    Bello, Celeste M.
    Sokol, Lubomir
    Sotomayor, Eduardo M.
    Tomblyn, Marcie
    Ayala, Ernesto
    [J]. BLOOD, 2012, 120 (21)
  • [38] Novel therapies for relapsed/refractory mantle cell lymphoma
    Arora, Puja C.
    Portell, Craig A.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (01) : 105 - 113
  • [39] Therapeutic options for relapsed/refractory mantle cell lymphoma
    Eyre, Toby A.
    Cheah, Chan Y.
    Wang, Michael L.
    [J]. BLOOD, 2022, 139 (05) : 666 - 677
  • [40] Ibrutinib-a new standard treatment for relapsed mantle cell lymphoma?
    Martin, Peter
    [J]. LANCET, 2016, 387 (10020): : 728 - 729
12345